Home | Site Map | Contact
You are here: Home » Molecular Pharming: High Level Plant Protein Expression (CPMV-HT) » Medicago Information

Medicago

The CPMV-HT expression system is already applied industrially. It has been licensed to Medicago Inc. (Quebec, Canada) and several vaccines are currently in clinical trials.

Medicago press releases

Medicago's vaccine candidate against novel influenza A (H1N1) virus immunogenic in mice  -  3 June 2009

QUEBEC CITY - June 30, 2009 - Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received positive results from an immunogenicity study in mice with the Company's new vaccine candidate for the influenza A (H1N1) virus, also known as swine flu. Results demonstrated that the Company's H1 VLP vaccine induced a positive immune response in mice against the H1N1 influenza virus. Medicago produced the H1 VLP antigen within 14 days of receiving the DNA sequence with its VLP vaccine technology and Proficia™ manufacturing technology.

Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine  -  1 November 2010

Medicago reports positive Phase II final results for its avian flu pandemic vaccine  -  30 June 2011

Medicago commences operations at its state-of-the-art vaccine facility in North Carolina  -  13 September 2011

 

PBL press releases 

Medicago and PBL sign license agreements for PBL’s bipartite expression and related technologies  -  8 August 2006

Medicago Receives 2009 Genesis Innovation Award  -  15 May 2009

Medicago selected to collaborate with IDRI on a multimillion dollar grant awarded to IDRI from the US Department of Defense  -  11 January 2011

CONGRATULATIONS to Prof George Lomonossoff  -  28 March 2012

Medicago announces agreement to be acquired by Mitsubishi Tanabe Pharma in a transaction valued at $357M  -  12 July 2013

PBL's partner Medicago announces new contract to explore production of Ebola antibodies  -  24 February 2015 

 

Medicago’s virus-like particle


 

Back to top